Immatics, today announced that it has initiated enrollment of patients into a phase I trial of IMA203, its third T-cell receptor (TCR)-transduced adoptive cell therapy program. IMA203 is an investigational immunotherapy which uses Immatics’ proprietary ACTengine® approach and is based on genetic engineering of the patient’s own T cells to express an exogenous TCR. The goal is to redirect and activate the T cells to treat solid tumors.
Immatics Initiates Third Phase I Clinical Trial of its Unique ACTengine® Platform in Patients with Advanced Solid Cancers
Immatics announces Clinical Trial Collaboration in Immunotherapy for Solid Cancers
Immatics today announced a collaboration with Roche to evaluate the safety and efficacy of IMA101, Immatics’ investigational autologous cell therapy, in combination with atezolizumab (TECENTRIQ®), in patients with solid cancers.
US Patent Office Grants the 100th Patent to Immatics Underpinning the Company’s Leading Role in the Field of Innovative Immunotherapies
Immatics Biotechnologies GmbH, today announced that the United States Patent and Trademark Office has issued the 100th patent to Immatics.